Despite almost universal testing for human-epidermal-growth-factor-receptor-2 (HER2), many women with a HER2-positive cancer may not receive trastuzumab. Fewer women received the newer gene-expression-profile (GEP) test.
Michele Toscano, MS
Advertisement
Articles by Michele Toscano, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently
2
Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains
3
Study Finds Flaw in Method for Key Oncology Value-Based Care Model
4
Defunding Co-Payment Assistance Disrupted nAMD Care
5